Pub Date : 2025-03-01Epub Date: 2025-01-24DOI: 10.1097/YCO.0000000000000977
Miguel Restrepo-Martinez, Vaughan Bell, Jesus Ramirez-Bermudez
Purpose of review: Autoimmune diseases such as systemic lupus erythematosus (SLE), multiple sclerosis (MS), and autoimmune encephalitis can directly and indirectly affect brain function, leading to cognitive dysfunction or well characterized neurocognitive syndromes. However, these are often poorly characterized in the literature. Here, we review evidence on clinical manifestations, risk factors, their assessment and outcomes, and evidence for underlying mechanisms and associated biomarkers, if available.
Recent findings: Significant advances have been made in neurocognitive disorders associated with four categories of autoimmune disease: neurocognitive disorders due to autoimmune connective tissue diseases, neurocognitive disorders due to autoimmune demyelinating diseases of the CNS, neurocognitive disorders due to autoimmune encephalitis, and neurocognitive disorders due to cerebrovascular disease of autoimmune origin.
Summary: Autoimmune diseases should be considered as critical causal factors underlying new cases of neurocognitive disorder, especially in young patients. These diseases are mediated by immune system reactions involving antibody production, T-cell-mediated damage, and demyelination. Although the prognosis seems favourable in most conditions after immunotherapy, the magnitude of the therapeutic effect of immunotherapy on cognitive functioning remains unclear.
{"title":"Cognitive disorders in patients with neuroimmunological disease.","authors":"Miguel Restrepo-Martinez, Vaughan Bell, Jesus Ramirez-Bermudez","doi":"10.1097/YCO.0000000000000977","DOIUrl":"10.1097/YCO.0000000000000977","url":null,"abstract":"<p><strong>Purpose of review: </strong>Autoimmune diseases such as systemic lupus erythematosus (SLE), multiple sclerosis (MS), and autoimmune encephalitis can directly and indirectly affect brain function, leading to cognitive dysfunction or well characterized neurocognitive syndromes. However, these are often poorly characterized in the literature. Here, we review evidence on clinical manifestations, risk factors, their assessment and outcomes, and evidence for underlying mechanisms and associated biomarkers, if available.</p><p><strong>Recent findings: </strong>Significant advances have been made in neurocognitive disorders associated with four categories of autoimmune disease: neurocognitive disorders due to autoimmune connective tissue diseases, neurocognitive disorders due to autoimmune demyelinating diseases of the CNS, neurocognitive disorders due to autoimmune encephalitis, and neurocognitive disorders due to cerebrovascular disease of autoimmune origin.</p><p><strong>Summary: </strong>Autoimmune diseases should be considered as critical causal factors underlying new cases of neurocognitive disorder, especially in young patients. These diseases are mediated by immune system reactions involving antibody production, T-cell-mediated damage, and demyelination. Although the prognosis seems favourable in most conditions after immunotherapy, the magnitude of the therapeutic effect of immunotherapy on cognitive functioning remains unclear.</p>","PeriodicalId":11022,"journal":{"name":"Current Opinion in Psychiatry","volume":"38 2","pages":"126-133"},"PeriodicalIF":7.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01Epub Date: 2025-01-22DOI: 10.1097/YCO.0000000000000978
Danit G Saks, Perminder S Sachdev
Purpose of review: Recent advancements in molecular biomarkers and therapeutic options for Alzheimer's disease have brought into focus the need for greater progress in the second most common cause of dementia, vascular cognitive impairment and dementia (VCID). We examine how the study of monogenic causes of VCID has contributed to the understanding of its pathophysiology and potential biomarker and treatment research.
Recent findings: It is widely accepted that conditions which disrupt the cerebral small vessels contribute to vascular pathologies including stroke and cerebral microbleeds, ultimately leading to vascular cognitive impairment and dementia. Among these conditions are a range of monogenic small vessel diseases (SVDs) such as CADASIL, CARASIL, Fabry disease and COL4A-related disorders.
Summary: This review indicates the importance of furthering research into monogenic SVDs in order to gain insight into the pathomechanisms of VCID more broadly. Monogenic conditions are easier to model than sporadic VCID and can serve as a guide for identifying biomarkers for diagnosis, monitoring and intervention outcomes.
{"title":"Monogenic causes of cerebral small vessel disease- models for vascular cognitive impairment and dementia?","authors":"Danit G Saks, Perminder S Sachdev","doi":"10.1097/YCO.0000000000000978","DOIUrl":"10.1097/YCO.0000000000000978","url":null,"abstract":"<p><strong>Purpose of review: </strong>Recent advancements in molecular biomarkers and therapeutic options for Alzheimer's disease have brought into focus the need for greater progress in the second most common cause of dementia, vascular cognitive impairment and dementia (VCID). We examine how the study of monogenic causes of VCID has contributed to the understanding of its pathophysiology and potential biomarker and treatment research.</p><p><strong>Recent findings: </strong>It is widely accepted that conditions which disrupt the cerebral small vessels contribute to vascular pathologies including stroke and cerebral microbleeds, ultimately leading to vascular cognitive impairment and dementia. Among these conditions are a range of monogenic small vessel diseases (SVDs) such as CADASIL, CARASIL, Fabry disease and COL4A-related disorders.</p><p><strong>Summary: </strong>This review indicates the importance of furthering research into monogenic SVDs in order to gain insight into the pathomechanisms of VCID more broadly. Monogenic conditions are easier to model than sporadic VCID and can serve as a guide for identifying biomarkers for diagnosis, monitoring and intervention outcomes.</p>","PeriodicalId":11022,"journal":{"name":"Current Opinion in Psychiatry","volume":" ","pages":"112-118"},"PeriodicalIF":7.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789596/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01Epub Date: 2024-12-16DOI: 10.1097/YCO.0000000000000984
Rosalyn Kefas, Raymond Roy, Amedeo D'Angiulli
Purpose of review: Using advanced bibliometric analysis, we systematically mapped the most current literature on urban air pollution and neurodevelopmental conditions to identify key patterns and associations. Here, we review the findings from the broader literature by discussing a distilled, validated subset of 44 representative studies.
Recent findings: Literature highlights a complex relationship between environmental toxins, neurodevelopmental disorders in children, and neurobehavioral pathways involving oxidative stress, neuroinflammation, and protein aggregation. Chronic prenatal and postnatal exposure to airborne pollutants - such as particulate matter and heavy metals - may contribute to early formation of amyloid plaques through preadolescence. These processes may compromise synaptic plasticity and neural integrity, which can progressively induce cognitive, emotional, and behavioral dysregulation, sharing some pathological features traditionally associated with adult neurodegenerative diseases.
Summary: The interactions between air pollution exposure levels, developmental timing, and factors such as genetic vulnerability associated with neurodevelopmental disorders are still undetermined. However, accelerated neurodegenerative processes leading to cognitive decline and suboptimal mental health in children and adolescents seem most likely linked with pollutants penetrating the blood-brain barrier, and inducing oxidative stress and neuroinflammation. Urgent precautionary action might reduce environmental exposures during critical early developmental periods, thereby safeguarding children's cognitive function and mental health.
{"title":"Urban air pollution and child neurodevelopmental conditions: a systematic bibliometric review.","authors":"Rosalyn Kefas, Raymond Roy, Amedeo D'Angiulli","doi":"10.1097/YCO.0000000000000984","DOIUrl":"10.1097/YCO.0000000000000984","url":null,"abstract":"<p><strong>Purpose of review: </strong>Using advanced bibliometric analysis, we systematically mapped the most current literature on urban air pollution and neurodevelopmental conditions to identify key patterns and associations. Here, we review the findings from the broader literature by discussing a distilled, validated subset of 44 representative studies.</p><p><strong>Recent findings: </strong>Literature highlights a complex relationship between environmental toxins, neurodevelopmental disorders in children, and neurobehavioral pathways involving oxidative stress, neuroinflammation, and protein aggregation. Chronic prenatal and postnatal exposure to airborne pollutants - such as particulate matter and heavy metals - may contribute to early formation of amyloid plaques through preadolescence. These processes may compromise synaptic plasticity and neural integrity, which can progressively induce cognitive, emotional, and behavioral dysregulation, sharing some pathological features traditionally associated with adult neurodegenerative diseases.</p><p><strong>Summary: </strong>The interactions between air pollution exposure levels, developmental timing, and factors such as genetic vulnerability associated with neurodevelopmental disorders are still undetermined. However, accelerated neurodegenerative processes leading to cognitive decline and suboptimal mental health in children and adolescents seem most likely linked with pollutants penetrating the blood-brain barrier, and inducing oxidative stress and neuroinflammation. Urgent precautionary action might reduce environmental exposures during critical early developmental periods, thereby safeguarding children's cognitive function and mental health.</p>","PeriodicalId":11022,"journal":{"name":"Current Opinion in Psychiatry","volume":" ","pages":"87-94"},"PeriodicalIF":7.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01Epub Date: 2025-01-22DOI: 10.1097/YCO.0000000000000980
Alessandro Dinoto, Eoin P Flanagan
Purpose of review: The aim of this review is to summarize clinical, radiological and laboratory findings in autoimmune dementia, to help clinicians in promptly identify this elusive condition.
Recent findings: The rapid advances in the field of autoimmune neurology have led to the discovery of novel antibodies and associated disorders, which are more frequent than previously hypothesized. The correct and prompt identification of cognitive decline of autoimmune origin is vital to ensure early treatment and better outcomes. The diagnosis of autoimmune dementia relies on specific clinical and radiological features and on the detection of specific autoantibodies. Autoantibody specificities predict response to treatment and the occurrence of cancer. In recent years, the differential diagnosis of autoimmune dementia has become more relevant, as the overinterpretation of antibody results, clinical and radiological findings may lead to an erroneous diagnosis of autoimmune dementia, with potential harm to patients due to inappropriate exposure to immunosuppressants.
Summary: Autoimmune dementia is a potentially treatable condition and should not be missed in clinical practice given the potential for reversibility with immunotherapy. The diagnosis of autoimmune dementia relies on a comprehensive review of clinical, radiological and laboratory data, and exclusion of other causes of dementia.
{"title":"Autoimmune dementia.","authors":"Alessandro Dinoto, Eoin P Flanagan","doi":"10.1097/YCO.0000000000000980","DOIUrl":"10.1097/YCO.0000000000000980","url":null,"abstract":"<p><strong>Purpose of review: </strong>The aim of this review is to summarize clinical, radiological and laboratory findings in autoimmune dementia, to help clinicians in promptly identify this elusive condition.</p><p><strong>Recent findings: </strong>The rapid advances in the field of autoimmune neurology have led to the discovery of novel antibodies and associated disorders, which are more frequent than previously hypothesized. The correct and prompt identification of cognitive decline of autoimmune origin is vital to ensure early treatment and better outcomes. The diagnosis of autoimmune dementia relies on specific clinical and radiological features and on the detection of specific autoantibodies. Autoantibody specificities predict response to treatment and the occurrence of cancer. In recent years, the differential diagnosis of autoimmune dementia has become more relevant, as the overinterpretation of antibody results, clinical and radiological findings may lead to an erroneous diagnosis of autoimmune dementia, with potential harm to patients due to inappropriate exposure to immunosuppressants.</p><p><strong>Summary: </strong>Autoimmune dementia is a potentially treatable condition and should not be missed in clinical practice given the potential for reversibility with immunotherapy. The diagnosis of autoimmune dementia relies on a comprehensive review of clinical, radiological and laboratory data, and exclusion of other causes of dementia.</p>","PeriodicalId":11022,"journal":{"name":"Current Opinion in Psychiatry","volume":"38 2","pages":"101-111"},"PeriodicalIF":7.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01Epub Date: 2024-12-20DOI: 10.1097/YCO.0000000000000985
Lee Wachtel, James Luccarelli, John Michael Falligant, Joshua Ryan Smith
Purpose of review: Over the last quarter century, the clinical evidence surrounding the use of electroconvulsive therapy (ECT) in individuals with autism spectrum disorder (ASD) has expanded. This review provides the most up-to-date findings on the usage of ECT in ASD and discusses these results within the historical context and direct patient care experience.
Recent findings: ECT is typically implemented for psychotropic-refractory catatonic, affective, psychotic, and combined pathology for individuals across the lifespan. Although highly stigmatized, ECT is well tolerated, efficacious, and potentially lifesaving for select individuals. A case presentation of an individual with autism as well as a summary of legal restrictions hampering his ECT access is presented.
Summary: ECT is increasingly used in individuals with ASD who present with a wide range of ECT-responsive psychopathology, as well as repetitive self-injury and late, autistic-like regression for which no cause is found. ECT is well tolerated and offers real hope for many ASD individuals with devastating, treatment-refractory conditions.
{"title":"Electroconvulsive therapy in autism spectrum disorders: an update to the literature.","authors":"Lee Wachtel, James Luccarelli, John Michael Falligant, Joshua Ryan Smith","doi":"10.1097/YCO.0000000000000985","DOIUrl":"10.1097/YCO.0000000000000985","url":null,"abstract":"<p><strong>Purpose of review: </strong>Over the last quarter century, the clinical evidence surrounding the use of electroconvulsive therapy (ECT) in individuals with autism spectrum disorder (ASD) has expanded. This review provides the most up-to-date findings on the usage of ECT in ASD and discusses these results within the historical context and direct patient care experience.</p><p><strong>Recent findings: </strong>ECT is typically implemented for psychotropic-refractory catatonic, affective, psychotic, and combined pathology for individuals across the lifespan. Although highly stigmatized, ECT is well tolerated, efficacious, and potentially lifesaving for select individuals. A case presentation of an individual with autism as well as a summary of legal restrictions hampering his ECT access is presented.</p><p><strong>Summary: </strong>ECT is increasingly used in individuals with ASD who present with a wide range of ECT-responsive psychopathology, as well as repetitive self-injury and late, autistic-like regression for which no cause is found. ECT is well tolerated and offers real hope for many ASD individuals with devastating, treatment-refractory conditions.</p>","PeriodicalId":11022,"journal":{"name":"Current Opinion in Psychiatry","volume":" ","pages":"79-86"},"PeriodicalIF":7.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12136711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01Epub Date: 2024-12-26DOI: 10.1097/YCO.0000000000000987
Joyla A Furlano, Maira Okada de Oliveira, Maritza Pintado-Caipa, Susanne Röhr
Purpose of review: To highlight recent findings on the prevalence and risk and protective factors for dementia in Indigenous Peoples, who are disproportionately affected by health inequities driven by social determinants of health and historical injustices. With increasing numbers of Indigenous individuals entering older age, there is a growing need for research to better understand dementia and opportunities for prevention in Indigenous Peoples.
Recent findings: Recent studies highlight a wide range of dementia prevalence across Indigenous Peoples, with estimates varying significantly by methodology, socio-cultural context, and region with stark gaps in regional representation. Studies suggested that Indigenous Peoples show distinct profiles of dementia risk factors, including higher rates of cardiovascular disease, lower educational attainment, and socioeconomic disadvantage. However, traditional lifestyles, strong social ties, and culturally grounded practices are suggested to offer protective effects against cognitive decline.
Summary: Despite growing research attention, significant limitations remain in understanding dementia in Indigenous Peoples. The available evidence points to the need for culturally sensitive approaches in research and dementia prevention, as well as greater consideration of the social and environmental factors shaping brain health. Future research should aim to incorporate Indigenous knowledge systems and address the social determinants of dementia risk in Indigenous Peoples.
{"title":"Dementia prevalence and dementia risk in Indigenous Peoples: recent findings, current developments, and future directions.","authors":"Joyla A Furlano, Maira Okada de Oliveira, Maritza Pintado-Caipa, Susanne Röhr","doi":"10.1097/YCO.0000000000000987","DOIUrl":"10.1097/YCO.0000000000000987","url":null,"abstract":"<p><strong>Purpose of review: </strong>To highlight recent findings on the prevalence and risk and protective factors for dementia in Indigenous Peoples, who are disproportionately affected by health inequities driven by social determinants of health and historical injustices. With increasing numbers of Indigenous individuals entering older age, there is a growing need for research to better understand dementia and opportunities for prevention in Indigenous Peoples.</p><p><strong>Recent findings: </strong>Recent studies highlight a wide range of dementia prevalence across Indigenous Peoples, with estimates varying significantly by methodology, socio-cultural context, and region with stark gaps in regional representation. Studies suggested that Indigenous Peoples show distinct profiles of dementia risk factors, including higher rates of cardiovascular disease, lower educational attainment, and socioeconomic disadvantage. However, traditional lifestyles, strong social ties, and culturally grounded practices are suggested to offer protective effects against cognitive decline.</p><p><strong>Summary: </strong>Despite growing research attention, significant limitations remain in understanding dementia in Indigenous Peoples. The available evidence points to the need for culturally sensitive approaches in research and dementia prevention, as well as greater consideration of the social and environmental factors shaping brain health. Future research should aim to incorporate Indigenous knowledge systems and address the social determinants of dementia risk in Indigenous Peoples.</p>","PeriodicalId":11022,"journal":{"name":"Current Opinion in Psychiatry","volume":" ","pages":"119-125"},"PeriodicalIF":7.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2024-11-07DOI: 10.1097/YCO.0000000000000975
Tomasz M Gondek, Tomasz Adamowski, Jolanta Janus, Ewelina Cichoń, Sylwia Paciorek, Mariusz Zięba, Alicja Bukowska, Agata Todzia-Kornaś, Andrzej Kiejna
Purpose of review: People with mental disorders in Poland have increased standardized mortality ratios (SMRs). This is the first study to assess all-cause mortality in people with mental disorders in Poland during the COVID-19 pandemic.
Recent findings: A nationwide, register-based cohort study utilizing data from the registry of healthcare services (2011-2020) and the all-cause death registry (2021) in Poland was conducted. Individuals who were consulted or hospitalized in public mental healthcare facilities and received at least one diagnosis of mental disorders (ICD-10) from 2011 to 2020 were identified. SMRs were compared between people with a history of mental disorder and the general population. SMRs for the pandemic period were also compared with prepandemic SMRs calculated for 2019.No significant differences in SMRs were observed overall between 2021 and 2019. A minor increase in SMR was observed in 2021 for people treated only in outpatient mental health clinics. In 2021, a significant decrease in SMRs was shown for individuals with diagnoses from groups F10-F19 and F20-F29, and a significant increase in SMRs was observed for those with diagnoses from group F40-F48.
Summary: SMRs for people with any mental disorder in Poland in 2021 remained at comparable levels to those in 2019.
{"title":"Mortality in people with mental disorders in Poland during the COVID-19 pandemic: a nationwide, register-based cohort study.","authors":"Tomasz M Gondek, Tomasz Adamowski, Jolanta Janus, Ewelina Cichoń, Sylwia Paciorek, Mariusz Zięba, Alicja Bukowska, Agata Todzia-Kornaś, Andrzej Kiejna","doi":"10.1097/YCO.0000000000000975","DOIUrl":"10.1097/YCO.0000000000000975","url":null,"abstract":"<p><strong>Purpose of review: </strong>People with mental disorders in Poland have increased standardized mortality ratios (SMRs). This is the first study to assess all-cause mortality in people with mental disorders in Poland during the COVID-19 pandemic.</p><p><strong>Recent findings: </strong>A nationwide, register-based cohort study utilizing data from the registry of healthcare services (2011-2020) and the all-cause death registry (2021) in Poland was conducted. Individuals who were consulted or hospitalized in public mental healthcare facilities and received at least one diagnosis of mental disorders (ICD-10) from 2011 to 2020 were identified. SMRs were compared between people with a history of mental disorder and the general population. SMRs for the pandemic period were also compared with prepandemic SMRs calculated for 2019.No significant differences in SMRs were observed overall between 2021 and 2019. A minor increase in SMR was observed in 2021 for people treated only in outpatient mental health clinics. In 2021, a significant decrease in SMRs was shown for individuals with diagnoses from groups F10-F19 and F20-F29, and a significant increase in SMRs was observed for those with diagnoses from group F40-F48.</p><p><strong>Summary: </strong>SMRs for people with any mental disorder in Poland in 2021 remained at comparable levels to those in 2019.</p>","PeriodicalId":11022,"journal":{"name":"Current Opinion in Psychiatry","volume":" ","pages":"3-34"},"PeriodicalIF":7.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2024-08-26DOI: 10.1097/YCO.0000000000000968
Paul M G Emmelkamp, Katharina Meyerbröker
Purpose of review: To provide an update of systematic reviews, meta-analyses and recent clinical outcome studies for personality disorder (PD) in order to investigate the state of the art of the evidence of psychotherapy for personality disorders.
Recent findings: Few outcome studies in patients with Cluster A and Cluster C PD have been conducted, which limits the conclusions which can be drawn. Most recently published research has been conducted with borderline PD. There is limited evidence that dialectical behavior therapy (DBT), mentalization based therapy and schema therapy are more effective than treatment as usual. There is no convincing evidence that long and intensive therapy is more effective than short and less intensive therapy. Drop-out is rather high for patients with borderline PD. Group therapy results in more drop-outs than individual therapy.
Summary: There is a clear need of studies evaluating whether psychotherapies developed for PDs are more effective than CBT for patients with Cluster C PD. Given that studies with patients with Cluster B PD suggest that longer treatment of DBT and mentalization-based treatment is not more effective than shorter treatment this needs to be studied with other evidence-based therapies as well. Serious efforts are needed to evaluate therapies for patients with Cluster A PDs.
综述目的:提供有关人格障碍(PD)的系统综述、荟萃分析和最新临床结果研究的最新情况,以调查人格障碍心理治疗证据的最新进展:针对 A 群和 C 群人格障碍患者的疗效研究很少,这限制了可得出的结论。最近发表的大多数研究都是针对边缘型人格障碍的。有有限的证据表明,辩证行为疗法(DBT)、心智化疗法和模式疗法比常规治疗更有效。没有令人信服的证据表明长期强化治疗比短期和低强度治疗更有效。边缘型帕金森病患者的辍学率相当高。总结:对于C群型帕金森病患者而言,显然有必要开展研究,评估针对帕金森病开发的心理疗法是否比CBT更有效。鉴于对B群型帕金森病患者的研究表明,DBT和基于精神化的较长时间治疗并不比较短时间治疗更有效,因此还需要对其他循证疗法进行研究。我们需要认真努力,评估针对 A 群型帕金森病患者的疗法。
{"title":"Psychotherapies for the treatment of personality disorders: the state of the art.","authors":"Paul M G Emmelkamp, Katharina Meyerbröker","doi":"10.1097/YCO.0000000000000968","DOIUrl":"10.1097/YCO.0000000000000968","url":null,"abstract":"<p><strong>Purpose of review: </strong>To provide an update of systematic reviews, meta-analyses and recent clinical outcome studies for personality disorder (PD) in order to investigate the state of the art of the evidence of psychotherapy for personality disorders.</p><p><strong>Recent findings: </strong>Few outcome studies in patients with Cluster A and Cluster C PD have been conducted, which limits the conclusions which can be drawn. Most recently published research has been conducted with borderline PD. There is limited evidence that dialectical behavior therapy (DBT), mentalization based therapy and schema therapy are more effective than treatment as usual. There is no convincing evidence that long and intensive therapy is more effective than short and less intensive therapy. Drop-out is rather high for patients with borderline PD. Group therapy results in more drop-outs than individual therapy.</p><p><strong>Summary: </strong>There is a clear need of studies evaluating whether psychotherapies developed for PDs are more effective than CBT for patients with Cluster C PD. Given that studies with patients with Cluster B PD suggest that longer treatment of DBT and mentalization-based treatment is not more effective than shorter treatment this needs to be studied with other evidence-based therapies as well. Serious efforts are needed to evaluate therapies for patients with Cluster A PDs.</p>","PeriodicalId":11022,"journal":{"name":"Current Opinion in Psychiatry","volume":" ","pages":"66-71"},"PeriodicalIF":7.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}